Acyclic And Contains At Least One Carbon Atom Between The Phosphorus Atoms Patents (Class 514/108)
  • Patent number: 10272052
    Abstract: Disclosed herein are compositions and methods for treating tauopathies such as Alzheimer's disease (AD). Also provided herein are methods of reducing or disrupting tau aggregation in a subject, and methods of reducing tau protein in a subject. The methods may include administering to the subject a therapeutic amount of hexachlorophene, or a pharmaceutically acceptable salt thereof. Further provided herein are pharmaceutical compositions comprising hexachlorophene, or a pharmaceutically acceptable salt thereof, for the treatment of a tauopathy in a subject.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: April 30, 2019
    Assignee: University of South Florida
    Inventors: Umesh Kumar Jinwal, Vetriselvan Manavalan
  • Patent number: 10195223
    Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form, can be used to treat or alleviate pain or related conditions.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: February 5, 2019
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 10052338
    Abstract: Oral dosage forms of osteoclast inhibitors, such as neridronic acid, in an acid form or a salt form can be used to treat or alleviate pain or related conditions, such as allodynia associated with complex regional pain syndrome.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: August 21, 2018
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 10039773
    Abstract: Oral dosage forms of osteoclast inhibitors, such as neridronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as arthritis.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: August 7, 2018
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 9999628
    Abstract: Osteoclast inhibitors, such as neridronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: June 19, 2018
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 9956234
    Abstract: Oral dosage forms of osteoclast inhibitors, such as neridronic acid and zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as joint pain.
    Type: Grant
    Filed: September 26, 2017
    Date of Patent: May 1, 2018
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 9937150
    Abstract: The present invention relates to a method for substituting for or acting with the hyperbaric oxygen therapy to improve hypoxia, comprising the step of: administrating a phthalide compound to a subject in need thereof, wherein the phthalide compound can increase the oxygen release efficiency of blood hemoglobin (Hb) in the subject and further increase the cellular oxygenation level, and when the phthalide compound substitutes for or act with the hyperbaric oxygen therapy, the common adverse side effects of the hyperbaric oxygen therapy, such as barotrauma, decompression sickness and oxygen poisoning, are prevented. The phthalide compound is used to substitute for or act with 2,3-BPG, to modulate and decrease the oxygen affinity of hemoglobin (Hb), to increase the oxygen release efficiency of hemoglobin (Hb) to tissue cells, thereby achieving a normal cellular oxygenation level and maintaining the cellular oxygenation level in a normal range.
    Type: Grant
    Filed: March 15, 2016
    Date of Patent: April 10, 2018
    Assignee: National Sun Yat-sen University
    Inventors: Chia-Chen Wang, Wei-Ren Chen
  • Patent number: 9931352
    Abstract: Oral dosage forms of osteoclast inhibitors, such as neridronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: April 3, 2018
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 9925260
    Abstract: The invention relates to the treatment of bone disorders. In particular, the invention is directed to the use of a dosing holiday to help overcome the resistance to anti-sclerostin antibodies which develops over time when a plurality of doses of antibody are given to a subject. By giving the subject to be treated such a dosing holiday, the subject may subsequently display an increased response to a subsequent dose of the anti-sclerostin antibody. The subject may be given multiple cycles of a batch of at least two doses of anti-sclerostin antibody and a dosing holiday. In some instances, the subject may be monitored to help determine when to give the dosing holiday. Further, the subject may be given a different treatment for the bone disorder during the dosing holiday from the anti-sclerostin antibody.
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: March 27, 2018
    Assignee: UCB PHARMA S.A.
    Inventor: Martyn Kim Robinson
  • Patent number: 9889225
    Abstract: A method for bone regeneration which comprises administering a short term release composition into a bone area of a subject in need thereof, wherein the composition comprises a poly(lactic-co-glycolic acid) cross-linked alendronate (PLGA-ALN), wherein the composition releases the alendronate into the bone area, wherein the bone tissue of the bone area is exposed in situ to a therapeutically effective amount of the alendronate over 9 days.
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: February 13, 2018
    Assignee: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Mei-Ling Ho, Je-Ken Chang, Rajalakshmanan Eswaramoorthy, Shun-Cheng Wu, Yao-Hsien Wang
  • Patent number: 9884069
    Abstract: Oral, parenteral, and intravenous dosage forms of osteoclast inhibitors, such as neridronic acid, can be used to treat or alleviate pain or related conditions, such as knee pain.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: February 6, 2018
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 9844559
    Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as bone marrow lesions.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: December 19, 2017
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 9844519
    Abstract: A method of treating TDP-43 proteinopathies such as Alzheimer's disease, amyotrophic lateral sclerosis, and fronto-temporal lobar dementia is presented herein. It was found that administering hexachlorophene to cells expressing endogenous TDP-43 or overexpressing wild-type TDP-43 reduced accumulation of TDP-43 in the cells.
    Type: Grant
    Filed: June 17, 2015
    Date of Patent: December 19, 2017
    Assignee: University of South Florida
    Inventors: Umesh K. Jinwal, Diego A. Peralta, Malathi Narayan
  • Patent number: 9795622
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions such as complex regional pain syndrome.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: October 24, 2017
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 9770457
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions such as bone marrow lesion.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: September 26, 2017
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 9545412
    Abstract: This invention relates to a composition comprising an anti-HIV treatment and a treatment for side effects of said anti-HIV treatment in an HIV-infected patient. This invention is, for example, very useful in the treatment of side effects caused by certain anti-HIV treatments, for example premature aging and lipodystrophy, which can be caused by protease inhibitors or reverse transcriptase inhibitors. The composition of this invention includes at least one hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, at least one farnesyl-pyrophosphate synthase inhibitor, and at least one anti-HIV agent. One of the processes for treating an HIV-infected patient includes, in any order, the following steps: (i) administration of a mixture including at least one hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor and at least one farnesyl-pyrophosphate synthase inhibitor and (ii) administration of an anti-HIV agent, in which the administrations are concomitant, successive or alternative.
    Type: Grant
    Filed: June 8, 2015
    Date of Patent: January 17, 2017
    Assignee: UNIVERSITE D'AIX-MARSEILLE
    Inventors: Pierre Cau, Nicolas Levy
  • Patent number: 9522157
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: December 20, 2016
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 9511081
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: December 6, 2016
    Assignee: Antecip Bioventures II, LLC
    Inventor: Herriot Tabuteau
  • Patent number: 9408861
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: August 9, 2016
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 9393252
    Abstract: The present invention is directed to antiviral compositions that provide efficacy against non-envelope viruses such as noroviruses. The antiviral compositions comprise an alcohol and a synergistic combination of an aromatic carboxylic acid and an aromatic hydroxyamide. The composition may be used as a topical on human skin, as a hand sanitizer or as a hard surface cleaning composition.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: July 19, 2016
    Assignee: ECOLAB USA INC.
    Inventors: Daniel E. Pedersen, Hilina Emiru, Carter Martin Silvernail
  • Patent number: 9211257
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: December 15, 2015
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventors: Herriot Tabuteau, Graeme Jones
  • Patent number: 9133236
    Abstract: Novel peptides are described which comprise an amino acid motif selected from the group consisting of “PG”, “GP”, “PI” and “IG” and having up to 10 amino acids upstream and/or downstream of the amino acid motif, wherein “P” in the motif is proline or hydroxyproline and the peptide stimulates the development, maintenance and repair of bone, cartilage and associated connective tissue. The invention further relates to pharmaceutical compositions of these peptides, as well as therapeutic and prophylactic uses of such peptides.
    Type: Grant
    Filed: February 17, 2009
    Date of Patent: September 15, 2015
    Inventors: Dennis R. Sindrey, Sydney M. Pugh, Timothy J. N. Smith
  • Patent number: 9095517
    Abstract: Described herein are dental compositions, articles of manufacture including such dental compositions, and methods of using such dental compositions. In some embodiments, the dental compositions include a combination of ascorbic acid with at least one of a hexametaphosphate and a beta glucans. In some instances, the dental compositions are included within an edible article, a chew, or an edible chew. Administration of the dental compositions to the oral cavity of a subject may reduce the gingival, plaque, and/or calculus scores of the subject over a defined time period.
    Type: Grant
    Filed: October 31, 2011
    Date of Patent: August 4, 2015
    Assignee: T.F.H. PUBLICATIONS, INC.
    Inventors: Glen S. Axelrod, Ajay Gajria
  • Publication number: 20150148312
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions.
    Type: Application
    Filed: January 23, 2015
    Publication date: May 28, 2015
    Inventors: Herriot Tabuteau, Graeme Jones
  • Publication number: 20150141374
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions.
    Type: Application
    Filed: January 28, 2015
    Publication date: May 21, 2015
    Inventors: Herriot Tabuteau, Graeme Jones
  • Publication number: 20150139909
    Abstract: The present invention relates to the field of osteoarthritis. More specifically, the present invention provides compositions and methods useful for treating or preventing osteoarthritis. In one embodiment, a method for treating or preventing osteoarthritis in a patient comprises the step of administering to the patient a therapeutically effective amount of a transforming growth factor beta (TGF-beta) inhibitor.
    Type: Application
    Filed: May 1, 2013
    Publication date: May 21, 2015
    Inventor: Xu Cao
  • Publication number: 20150141339
    Abstract: According to the invention there is provided a compound of formula (I): wherein R1, R2, R3 and n have meanings given in the description, or a pharmaceutically acceptable solvate, salt or prodrug thereof for use in the treatment of osteoporosis and/or osteopenia.
    Type: Application
    Filed: October 21, 2014
    Publication date: May 21, 2015
    Inventors: Stephen Hodges, Robin Soper
  • Publication number: 20150141373
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions.
    Type: Application
    Filed: January 28, 2015
    Publication date: May 21, 2015
    Inventors: Herriot Tabuteau, Graeme Jones
  • Publication number: 20150133403
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions.
    Type: Application
    Filed: January 26, 2015
    Publication date: May 14, 2015
    Inventors: Herriot Tabuteau, Graeme Jones
  • Publication number: 20150111859
    Abstract: Provided is a moisturizer having hygroscopicity and water retention ability, and also provided is a composition superior in antiseptic property and feeling on application, in addition to moisturizing property, and free of coloration and odorization. A moisturizer containing acylproline represented by the formula (1) wherein an acyl group represented by R1—CO— is an acyl group derived from a saturated or unsaturated fatty acid having 3-23 carbon atoms, or a salt thereof, and a composition containing (A) acylproline represented by the above formula (1) or a salt thereof and (B) bisphosphonate.
    Type: Application
    Filed: December 29, 2014
    Publication date: April 23, 2015
    Applicant: AJINOMOTO CO., INC.
    Inventors: Takanori SUGIMOTO, Nana HARAYA, Masatoshi SAITO
  • Patent number: 8974801
    Abstract: Pharmaceutical compositions for long-term sustained release of bisphosphonate drugs are provided. In one embodiment, the composition includes an aqueous suspension of a solid which includes a salt of a bisphosphonate drug and a salt of pentavalent phosphorus oxoacid. The compositions can be used to treat a variety of bone diseases, including osteoporosis.
    Type: Grant
    Filed: June 25, 2007
    Date of Patent: March 10, 2015
    Assignee: Amphastar Pharmaceuticals Inc.
    Inventors: Jack Yongfeng Zhang, Mary Ziping Luo, Dingyuan Fei, Kevin Xie, Jie Fei Ding
  • Patent number: 8968763
    Abstract: Disclosed herein are implantable medical devices comprising controlled release biodegradable block copolymers or coated with controlled release block copolymers and at least one drug releasable from the block copolymer. The controlled release block copolymers comprise least two blocks selected from the group consisting of polyesters, polyethers, and polyurethanes.
    Type: Grant
    Filed: February 19, 2010
    Date of Patent: March 3, 2015
    Assignee: Medtronic Vascular, Inc.
    Inventors: Ya Guo, Peiwen Cheng
  • Publication number: 20150057250
    Abstract: Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions.
    Type: Application
    Filed: November 7, 2014
    Publication date: February 26, 2015
    Inventor: Herriot Tabuteau
  • Publication number: 20150030541
    Abstract: The present invention provides phosphonate conjugates and methods of preparing the phosphonate conjugates so as to allow, for example, improved methods and compounds for modifying the surface of a nanoparticle to increase in vivo circulation times and targeted delivery performance.
    Type: Application
    Filed: October 14, 2014
    Publication date: January 29, 2015
    Inventor: Thomas E. Rogers
  • Patent number: 8940320
    Abstract: The invention relates to a dental implant, which comprises a coating at least in those surface areas that come into contact with hard and/or soft tissue when implanted. To ensure that the active ingredient contained in the coating (bisphosphonate) is released into the surrounding tissue or can act in the latter in a controlled manner at the correct speed, the coating is characterized in that it contains bisphosphonate, the respective pharmaceutically compatible salts or esters of the latter, in addition to at least one amphiphilic component, selected from the group containing branched or linear, substituted or unsubstituted, saturated or partially unsaturated C10-C30 alkyl-, alkenyl, alkylaryl-, aryl-, cycloalkyl-, alkylcycloalkyl-, alkylcycloaryl-carboxylates, -phosphates or -sulfates or mixtures thereof and/or a water-soluble ionic polymer component.
    Type: Grant
    Filed: October 17, 2006
    Date of Patent: January 27, 2015
    Assignee: Thommen Medical AG
    Inventors: Falko Schlottig, Matthias Schnabelrauch, Armin Rex Kautz
  • Patent number: 8933058
    Abstract: The present invention relates to a complex of a bisphosphonate compound, methods of preparing such complex and uses thereof.
    Type: Grant
    Filed: June 7, 2010
    Date of Patent: January 13, 2015
    Assignee: Nanyang Technological University
    Inventors: Subramanian Venkatraman, Say Chye Joachim Loo
  • Publication number: 20150005261
    Abstract: The invention provides methods for treating fibrosis, as well as methods for modulating mitochondrial peroxide production in a cell, and methods for modulating the import of Rac1 into the mitochondria of a cell.
    Type: Application
    Filed: April 25, 2014
    Publication date: January 1, 2015
    Applicant: University of Iowa Research Foundation
    Inventors: Raymond J. Hohl, A. Brent Carter
  • Publication number: 20140370100
    Abstract: A bone filler composition comprises a mixture of a curable calcium phosphate based bone filler which is formed from a liquid component and a calcium phosphate based powder component, and a formulation which comprises a bisphosphonate in particulate form. The particles of the bisphosphonate being embedded in particles of a polymeric material which resorbs when the formulation is implanted.
    Type: Application
    Filed: January 18, 2013
    Publication date: December 18, 2014
    Inventor: Saad Abdul Majeed Ali
  • Patent number: 8895056
    Abstract: The present invention relates to the regional delivery of therapeutic agents for the treatment of vascular diseases wherein regional delivery refers to delivery of a therapeutically effective amount of the therapeutic agent to an area of the vessel that includes not only afflicted tissue but non-afflicted tissue at the periphery of the afflicted tissue as well.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: November 25, 2014
    Assignee: Abbott Cardiovascular Systems Inc.
    Inventors: Stephen D. Pacetti, Paul M. Consigny, Ronald W. Heil, Jr., Florian Niklas Ludwig, Dariush Davalian, Li Zhao, Irina Astafieva, Jinping Wan, Fozan El-Nounou, Katsuyuki Murase, Syed F. A. Hossainy, Rachel Bright, Jeffrey Ellis
  • Publication number: 20140335048
    Abstract: This disclosure relates, at least in part, to a method of treatment. In one embodiment, the method of treatment comprises administering to a subject in need of such treatment a first therapeutic agent including compound (1): or a pharmaceutically acceptable salt thereof in combination with a second therapeutic agent, wherein the first therapeutic agent and the second therapeutic agent are administered either simultaneously or sequentially.
    Type: Application
    Filed: July 25, 2014
    Publication date: November 13, 2014
    Applicant: ONCOCEUTICS, INC.
    Inventors: Martin STOGNIEW, Joshua E. ALLEN
  • Patent number: 8883203
    Abstract: The invention relates to a pharmaceutical composition and oral dosage forms comprising a bisphosphonate in combination with an enhancer to enhance intestinal delivery of the bisphosphonate to the underlying circulation. Preferably, the enhancer is a medium chain fatty acid or a medium chain fatty acid derivative having a carbon chain length of from 6 to 20 carbon atoms, and the solid oral dosage form is a controlled release dosage form such as a delayed release dosage form.
    Type: Grant
    Filed: April 26, 2010
    Date of Patent: November 11, 2014
    Assignee: Merrion Research III Limited
    Inventor: Thomas W. I. Leonard
  • Publication number: 20140328793
    Abstract: Compounds, compositions, and methods of treatment and prevention of HIV infection are disclosed. The compounds are pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidine JAK inhibitors. Combinations of these JAK inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, and the like, are also disclosed. In one embodiment, the combinations include a combination of adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, optionally in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of HIV in an infected patient.
    Type: Application
    Filed: November 30, 2012
    Publication date: November 6, 2014
    Applicant: Emory University
    Inventors: Christina Gavegnano, Raymond F. Schinazi
  • Patent number: 8877196
    Abstract: The present invention provides a method of promoting local bone growth by administering a therapeutic amount of a Sost antagonist to a mammalian patient in need thereof. Preferably, the Sost antagonist is an antibody or FAB fragment selectively recognizing any one of SEQ ID NOS: 1-23. The Sost antagonist may be coadministered together or sequentially with a matrix conducive to anchoring new bone growth. Orthopedic and Periodontal devices comprising an implantable portion adapted to be permanently implanted within a mammalian body and bearing an external coating of a Sost antagonist are also disclosed, as it a method of increasing bone density by administering to a mammalian patient a therapeutic amount of a Sost antagonist together with an antiresorptive drug.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: November 4, 2014
    Assignee: OssiFi Inc.
    Inventor: Debra L. Ellies
  • Patent number: 8859530
    Abstract: A combination therapy for treating osteoarthritis is disclosed. The combination therapy includes the co-administration of a steroid and Zoledronic Acid. The coadministration of a steroid decreases the production of cytokines, and, therefore, decreases the pro-inflammatory effects of Zoledronic Acid. The co-administration of Zoledronic Acid with steroids treats osteoarthritis, and helps to prevent the onset of osteoarthritis in patients at risk for osteoarthritis.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: October 14, 2014
    Assignee: Voltarra Pharmaceuticals, Inc.
    Inventor: Ketan Desai
  • Publication number: 20140302166
    Abstract: This invention relates to a composition that comprises inositol phosphates and/or bisphosphonates, and to the use thereof to prevent the loss of substances of biological interest in the body of patients subjected to dialysis and to maintain sufficient physiological levels of said substances to regulate physiological and/or pathological processes, these substances being inhibitors of pathological crystallisation.
    Type: Application
    Filed: February 12, 2014
    Publication date: October 9, 2014
    Inventors: Félix GRASES FREIXEDAS, Joan PERELLO BESTARD, Fernando TUR ESPINOSA, Antonia COSTA BAUZA, Rafael M. PRIETO ALMIRALL, Isabel GOMILA MUÑIZ
  • Patent number: 8853187
    Abstract: The present invention relates to a composition for prevention and/or treatment of metabolic diseases of bones comprising at least one bisphosphonate; viscosity agents comprising carboxymethylcellulose and xanthan gum; at least one flavoring agent; and purified water; a process for preparing a composition according to the present invention; and use of such a composition for prevention, treatment and/or diagnosis of metabolic diseases of bones, especially for children.
    Type: Grant
    Filed: June 8, 2009
    Date of Patent: October 7, 2014
    Assignees: Gador S.A., University of Leiden
    Inventors: Daniel Zanetti, Damian Cairatti, Enrique Piccinni, Emilio J. A. Roldan, Socrates Papapoulos
  • Publication number: 20140296166
    Abstract: The present invention provides for methods and compositions for treating, reducing and/or preventing cardiac dysfunction by administering to subject a therapeutically effective amount of a bisphosphonate, prodrug thereof, functional analogue or a pharmaceutically effective salt thereof in an amount sufficient to increase activity of at least one kinase in heart tissue of the subject.
    Type: Application
    Filed: November 14, 2012
    Publication date: October 2, 2014
    Inventors: Kenneth W. Lyles, Cathleen S. Colon-Emeric, Christopher M. O'Connor, Dennis Abraham, Kent Nilson, Howard Rockman, Graham Russell
  • Publication number: 20140271825
    Abstract: The present invention provides liposomes loaded with chelating agents, pharmaceutical formulations including these liposomes and methods of making chelating agent liposomes. Because the chelating agents are loaded in the liposome with high efficiencies, the liposomes are of use in treatment of metal ion overload in subjects. The liposomes can include two or more different chelating agents of different structures and affinities for metal ions.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Inventors: Mark E. HAYES, Charles O. NOBLE, Francis C. SZOKA, JR.
  • Publication number: 20140274953
    Abstract: The described invention provides an ex vivo dynamic multiple myeloma (MM) cancer niche contained in a microfluidic device. The dynamic MM cancer niche includes (a) a three-dimensional tissue construct containing a dynamic ex vivo bone marrow (BM) niche, which contains a mineralized bone-like tissue containing viable osteoblasts self-organized into cohesive multiple cell layers and an extracellular matrix secreted by the viable adherent osteoblasts; and a microenvironment dynamically perfused by nutrients and dissolved gas molecules; and (b) human myeloma cells seeded from a biospecimen composition comprising mononuclear cells and the multiple myeloma cells. The human myeloma cells are in contact with osteoblasts of the BM niche, and the viability of the human myeloma cells is maintained by the MM cancer niche.
    Type: Application
    Filed: March 14, 2013
    Publication date: September 18, 2014
    Inventors: Woo Lee, Jenny Zilberberg, David Samuel Siegel, Peter Tolias, Hongjun Wang, Wenting Zhang
  • Publication number: 20140274905
    Abstract: The present invention generally relates to methods of modulating Cav1.2 channels and Cav1.2 channel activators.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Applicant: Duke University
    Inventors: Geoffrey S. Pitt, Adam S. Barnett, Xinhe Yin